Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.17)
# 1,166
Out of 4,740 analysts
191
Total ratings
43.81%
Success rate
2.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Upgrades: Overweight | $45 → $67 | $46.18 | +45.08% | 10 | Dec 13, 2024 | |
| FOLD Amicus Therapeutics | Downgrades: Equal-Weight | $17 → $12 | $9.65 | +24.35% | 4 | Dec 13, 2024 | |
| BIOA BioAge Labs | Initiates: Overweight | $40 | $5.30 | +654.72% | 1 | Oct 21, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $92 → $95 | $127.07 | -25.24% | 5 | Oct 11, 2024 | |
| CNTA Centessa Pharmaceuticals | Upgrades: Overweight | $11 → $26 | $16.28 | +59.71% | 1 | Sep 19, 2024 | |
| ENGN enGene Holdings | Maintains: Overweight | $40 | $7.29 | +448.70% | 2 | Sep 11, 2024 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Equal-Weight | $28 → $20 | $19.08 | +4.82% | 23 | Aug 7, 2024 | |
| CRVO CervoMed | Initiates: Overweight | $35 | $2.27 | +1,441.85% | 1 | Jul 26, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Equal-Weight | $160 → $150 | $122.48 | +22.47% | 4 | Jul 12, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $160 → $170 | $147.58 | +15.19% | 24 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $39.20 | +78.57% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $11.28 | +121.63% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $40 | $56.99 | -29.81% | 5 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $30.75 | +78.86% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $60 → $90 | $47.86 | +88.05% | 12 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.14 | +250.88% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $2.35 | +70.21% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $55 | $58.47 | -5.93% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.42 | +856.25% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $60 → $140 | $7.87 | +1,678.91% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $84 | $44.85 | +87.29% | 7 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $40 | $13.23 | +202.34% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $2.15 | +551.16% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $1.76 | +184.09% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.08 | +44.23% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.22 | +1,047.54% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $19 | $10.56 | +79.92% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 | $1.99 | +653.77% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $2.30 | +334.78% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $34.13 | -35.54% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $40.71 | +264.78% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $4.07 | +1,374.20% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $5.53 | +8.50% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.86 | +6,193.71% | 6 | May 8, 2020 |
PTC Therapeutics
Dec 13, 2024
Upgrades: Overweight
Price Target: $45 → $67
Current: $46.18
Upside: +45.08%
Amicus Therapeutics
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $9.65
Upside: +24.35%
BioAge Labs
Oct 21, 2024
Initiates: Overweight
Price Target: $40
Current: $5.30
Upside: +654.72%
Intra-Cellular Therapies
Oct 11, 2024
Maintains: Overweight
Price Target: $92 → $95
Current: $127.07
Upside: -25.24%
Centessa Pharmaceuticals
Sep 19, 2024
Upgrades: Overweight
Price Target: $11 → $26
Current: $16.28
Upside: +59.71%
enGene Holdings
Sep 11, 2024
Maintains: Overweight
Price Target: $40
Current: $7.29
Upside: +448.70%
ACADIA Pharmaceuticals
Aug 7, 2024
Downgrades: Equal-Weight
Price Target: $28 → $20
Current: $19.08
Upside: +4.82%
CervoMed
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $2.27
Upside: +1,441.85%
Jazz Pharmaceuticals
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $160 → $150
Current: $122.48
Upside: +22.47%
Neurocrine Biosciences
Jul 12, 2024
Maintains: Overweight
Price Target: $160 → $170
Current: $147.58
Upside: +15.19%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $39.20
Upside: +78.57%
Apr 30, 2024
Initiates: Overweight
Price Target: $25
Current: $11.28
Upside: +121.63%
Apr 2, 2024
Maintains: Equal-Weight
Price Target: $75 → $40
Current: $56.99
Upside: -29.81%
Feb 20, 2024
Initiates: Overweight
Price Target: $55
Current: $30.75
Upside: +78.86%
Jan 5, 2024
Downgrades: Equal-Weight
Price Target: $60 → $90
Current: $47.86
Upside: +88.05%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.14
Upside: +250.88%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $2.35
Upside: +70.21%
Dec 19, 2023
Upgrades: Overweight
Price Target: $29 → $55
Current: $58.47
Upside: -5.93%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.42
Upside: +856.25%
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $60 → $140
Current: $7.87
Upside: +1,678.91%
Nov 3, 2023
Maintains: Overweight
Price Target: $90 → $84
Current: $44.85
Upside: +87.29%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $13.23
Upside: +202.34%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $2.15
Upside: +551.16%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $1.76
Upside: +184.09%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.08
Upside: +44.23%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.22
Upside: +1,047.54%
Feb 3, 2023
Maintains: Overweight
Price Target: $27 → $19
Current: $10.56
Upside: +79.92%
Feb 3, 2023
Upgrades: Overweight
Price Target: $15
Current: $1.99
Upside: +653.77%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $2.30
Upside: +334.78%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $34.13
Upside: -35.54%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $40.71
Upside: +264.78%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $4.07
Upside: +1,374.20%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $5.53
Upside: +8.50%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.86
Upside: +6,193.71%